Testican-1-mediated epithelial-mesenchymal transition signaling confers acquired resistance to lapatinib in HER2-positive gastric cancer (Q39122676)

9 September 2017

title

Testican-1-mediated epithelial-mesenchymal transition signaling confers acquired resistance to lapatinib in HER2-positive gastric cancer (English)

1 reference

9 September 2017

H-P Kim

1

1 reference

9 September 2017

S-W Han

2

1 reference

9 September 2017

S-H Song

3

1 reference

9 September 2017

E-G Jeong

4

1 reference

9 September 2017

M-Y Lee

5

1 reference

9 September 2017

D Hwang

6

1 reference

9 September 2017

S-A Im

7

1 reference

9 September 2017

Y-J Bang

8

1 reference

9 September 2017

T-Y Kim

9

1 reference

9 September 2017

language of work or name

English

0 references

publication date

22 July 2013

1 reference

9 September 2017

1 reference

9 September 2017

volume

33

1 reference

9 September 2017

issue

25

1 reference

9 September 2017

page(s)

3334-3341

1 reference

HER2 in gastric cancer: a new prognostic factor and a novel therapeutic target

9 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1038/ONC.2013.285

Assessment of a HER2 scoring system for gastric cancer: results from a validation study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/ONC.2013.285

Amplification of HER-2 in gastric carcinoma: association with Topoisomerase IIalpha gene amplification, intestinal type, poor prognosis and sensitivity to trastuzumab.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/ONC.2013.285

Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/ONC.2013.285

The growth inhibitory effect of lapatinib, a dual inhibitor of EGFR and HER2 tyrosine kinase, in gastric cancer cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/ONC.2013.285

Lapatinib, a dual EGFR and HER2 tyrosine kinase inhibitor, downregulates thymidylate synthase by inhibiting the nuclear translocation of EGFR and HER2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/ONC.2013.285

Assessment of epidermal growth factor receptor (EGFR, ErbB1) and HER2 (ErbB2) protein expression levels and response to lapatinib (Tykerb, GW572016) in an expanded panel of human normal and tumour cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/ONC.2013.285

Epithelial versus mesenchymal phenotype determines in vitro sensitivity and predicts clinical activity of erlotinib in lung cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/ONC.2013.285

Epithelial to mesenchymal transition is a determinant of sensitivity of non-small-cell lung carcinoma cell lines and xenografts to epidermal growth factor receptor inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/ONC.2013.285

Restoring E-cadherin expression increases sensitivity to epidermal growth factor receptor inhibitors in lung cancer cell lines.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/ONC.2013.285

Gefitinib resistance of cancer cells correlated with TM4SF5-mediated epithelial–mesenchymal transition

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/ONC.2013.285

Acquisition of epithelial-mesenchymal transition phenotype of gemcitabine-resistant pancreatic cancer cells is linked with activation of the notch signaling pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/ONC.2013.285

Slug confers resistance to the epidermal growth factor receptor tyrosine kinase inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/ONC.2013.285

Epithelial-mesenchymal transitions in tumour progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/ONC.2013.285

Epithelial-mesenchymal transitions in development and disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/ONC.2013.285

Testican-1: a differentially expressed proteoglycan with protease inhibiting activities.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/ONC.2013.285

Downregulation of several fibulin genes in prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/ONC.2013.285

SPOCK1 is regulated by CHD1L and blocks apoptosis and promotes HCC cell invasiveness and metastasis in mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/ONC.2013.285

Novel markers for enterochromaffin cells and gastrointestinal neuroendocrine carcinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/ONC.2013.285

MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/ONC.2013.285

Antitumor activity of HM781-36B, an irreversible Pan-HER inhibitor, alone or in combination with cytotoxic chemotherapeutic agents in gastric cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/ONC.2013.285

Wnt signalling and its impact on development and cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/ONC.2013.285

Dysregulation of Wnt/β-Catenin Signaling in Gastrointestinal Cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/ONC.2013.285

Tankyrase inhibition stabilizes axin and antagonizes Wnt signalling

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/ONC.2013.285

Novel mechanism of lapatinib resistance in HER2-positive breast tumor cells: activation of AXL.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/ONC.2013.285

Acquired resistance to small molecule ErbB2 tyrosine kinase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/ONC.2013.285

A model of acquired autoresistance to a potent ErbB2 tyrosine kinase inhibitor and a therapeutic strategy to prevent its onset in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/ONC.2013.285

Lapatinib induces apoptosis in trastuzumab-resistant breast cancer cells: effects on insulin-like growth factor I signaling.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/ONC.2013.285

A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/ONC.2013.285

PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/ONC.2013.285

Lapatinib antitumor activity is not dependent upon phosphatase and tensin homologue deleted on chromosome 10 in ErbB2-overexpressing breast cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/ONC.2013.285

Expression of ER, PgR, HER1, HER2, and response: a study of preoperative chemotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/ONC.2013.285

Escape from HER-family tyrosine kinase inhibitor therapy by the kinase-inactive HER3

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/ONC.2013.285

Truncated ErbB2 receptor (p95ErbB2) is regulated by heregulin through heterodimer formation with ErbB3 yet remains sensitive to the dual EGFR/ErbB2 kinase inhibitor GW572016.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/ONC.2013.285

Biosynthesis of tumorigenic HER2 C-terminal fragments by alternative initiation of translation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/ONC.2013.285

Expression of p95HER2, a truncated form of the HER2 receptor, and response to anti-HER2 therapies in breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/ONC.2013.285

21 January 2018

Identifiers

DOI

10.1038/ONC.2013.285

1 reference

9 September 2017

1 reference